In collaboration with the National Cancer Institute (NCI), researchers at The Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD) have discovered monoclonal antibodies that bind to matrilin-3, a protein specifically expressed in cartilage tissue, that could be used for treating or inhibiting growth plate disorders, such as a skeletal dysplasia or short stature. The monoclonal antibodies can also be used to target therapeutic agents, such as those for anti-arthritis, to cartilage tissue. NICHD seeks statements of capability or interest from parties interested in collaborative research to co-develop, evaluate, and/or commercialize treatment of skeletal disorders using targeting antibodies.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research partners, co-development partners, and/or licensees for hydrogels that can be used in tissue repair. Gels typically exhibit a decrease in mechanical strength (e.g., elastic modulus) upon swelling of the particles. The gels of this technology, however, exhibit an increase in mechanical strength upon swelling. The gels are comprised of a crosslinked polymer matrix dispersed in a crosslinked polymer matrix.